Get started

BIO

$EDSAEdesa Biotech Inc (NASDAQ: EDSA) is surging higher Monday after the company announced positive Phase 2 data of its monoclonal antibody in hospitalized COVID-19 patients. Critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over standard of care. An independent Data and Safety Monitoring Board concluded that "a clinically important efficacy signal" was detected and that the study "met its objective." The DSMB recommended continuation of the study into a Phase 3 trial. "The strong effect in reducing death in the most critically ill hospitalized patients who have been treated with systemic corticosteroids, including dexamethasone, and IL-6 inhibitors, shows the potential life-saving impact of this drug, irrespective of SARS-CoV-2 variant," said Par Nijhawan, CEO of Edesa Biotech. Edesa Biotech is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases. Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
NASDAQ:EDSALong
by BADQOMOCAWGOWLD
LABD break outI have been tackling LABD/LABU day in and day out. I have somehow made some profit week by week. I am trying to figure out which was the better trade as I think it has come to the tipping point. I believe LABD is the winner. I see bearish sentiment in the short term market and I see an inverse head and shoulders or a cup and handle formation. On LABU I confirmed it because whichever way I look at it it is the opposite, head and shoudler pattern, inverse cup and handle.
AMEX:LABDLong
by umaidsiddiqui786
MIRO Miromatrix Medical Price TargetMiromatrix Medical Inc. engages in the development of biological human organs to solve the chronic shortage of transplantable organs. 114,000 people in the U.S. are waiting for a life-saving organ transplant, and more than half will die due to a lack of available organs. Miromatrix Medical trial is expected to begin in the second half of 2022 and will assess the function of a bioengineered liver in humans via an external application. if it succeeds, the opportunity to buy the stock at these prices will be history. The Market Cap of MIRO is just 214.74Mil On 7/19/2021 Craig Hallum brokerage Initiated Coverage with a Buy rating and a $22.00 price target
MLong
by TopgOptions
ABCL - 20-30% UPSIDE - LONGAll, ABCL is for massively oversold on weekly down so regardless how you feel about the stock (even though price target analysts are WAY higher) this is due for a rip. Not to mention this is a perfect situation for institutions to enter into ABCL at a pretty big discount from fair value etc. I am temporarily waiting next few days watch it extremely closely then entering unless it breaks through the bottom. Feel free to do your DD on ABCL they actually have really good positive pipelines just being held down.
NASDAQ:ABCLLong
by DigitalData
HAPP - ABOUT TO BE HAPPENINGNo there is nothign wrong with this stock its a typical bio downtrend. I think this is due for a massssssssive move. I actually rarely pay much attention to indicators regardless how many I have / most the time zoomed in double clicked in just using volume etc. However, to find end of long term downtrends they can be extremely useful on these. Bollinger Bands (40 day and 14 day overalapping on bottom) RSI dead on all time frames Factors: -Float 16M when this moves it will move even bigger -Cash to Debt 18 RATIO. They are not at all hurting for cash in fact did direct offering also. Cash is without a doubt good for future far as I can tell. -Postitive news / Ecommerce etc. I think it pops VERY similar to WNW
HLong
by DigitalData
$NMRD entry PTs 10-12 PT 18-19 and higher Nemaura Medical (NMRD) said early Wednesday it received a purchase order for 200,000 sugarBEAT sensors and 5,000 sugarBEAT transmitters from its UK licensee DB Ethitronix. Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. The company provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients. It has a license agreement with Healthimation, LLC, which licenses the company to make, have made, use, offer to sell, sell, and import intensive medical diabetes and weight management program for Type 2 diabetes, prediabetes, and general wellness; the Why WAIT app; and common law trademarks which incorporate the mark WHY WAIT or WHYWAIT and the use of licensed marks. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
NLong
by UnknownUnicorn19246015
$VXRT entry PT 7-8 PT Target PTs 14-17-22Trend-base Fib Extension... Why Vaxart Stock Is Surging Today Investors are excited about the company's experimental COVID-19 vaccine. What happened Shares of Vaxart (NASDAQ:VXRT) climbed on Tuesday after the biotech released promising data from a clinical trial of its oral coronavirus vaccine candidate. As of 3:30 p.m. EDT, Vaxart's stock price was up more than 12%. So what A phase 1 study showed Vaxart's vaccine to potentially be protective against COVID-19, as well as a broad array of other coronavirus-induced illnesses, such as SARS, MERS, and the common cold. "Our vaccine's immune response appears very different than that seen from the leading injectables: mucosal antibodies rather than serum antibodies, and more potent T-cell responses," Vaxart CEO Andrei Floroiu said in a press release. T-cells are a type of white blood cells that can seek out and kill virus-infected cells. They are a vital part of the body's ability to generate an adaptive immune response to specific pathogens. Vaxart's drug produced a stronger T-cell response than Pfizer and Moderna's injectable vaccines, according to Vaxart's chief scientific officer, Dr. Sean Tucker. Now what Should Vaxart's vaccine candidate prove to be safe and effective in later-stage clinical trials, it could become a welcomed new tool in the battle against COVID-19. In such a scenario, the drug would also provide Vaxart with a powerful new revenue and profit driver. Joe Tenebruso (TMFGuardian)
V
by UnknownUnicorn19246015
$ATOS entry PTs 2.30 Target PTs 4.75-5.50-7 and higherPivoting off Support and up-trending towards Resistance, time sequence within Wave analysis Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
NASDAQ:ATOSLong
by BADQOMOCAWGOWLD
$BCTX PT 4-4.50BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
NASDAQ:BCTXLong
by UnknownUnicorn19246015